- Stoke Therapeutics press release (NASDAQ:STOK): Q4 GAAP EPS of -$0.18 beats by $0.35.
- Revenue of $22.61M (+707.1% Y/Y) beats by $18.33M.
- As of December 31, 2024, the company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028.
Stoke Therapeutics GAAP EPS of -$0.18 beats by $0.35, revenue of $22.6M beats by $18.33M
